Clene: 96% of CNM-Au8-treated MS patients with vision gains also showed MRI remyelination evidence

Clene Inc.

96% of LCLA visual responders had improved MRI DTI metrics (AD/MTR), confirming remyelination and neuronal repair.
91% of LCLA visual responders showed multi-focal VEP improvements (latency/amplitude), indicating functional recovery.
98% of SDMT cognitive responders exhibited corresponding MRI DTI improvements, linking cognitive gains to repair.
Data from long-term open-label extension of Phase 2 VISIONARY-MS trial presented at AAN 2025 Late-Breaking Science Session.
Clene plans to confirm findings in a global Phase 3 trial for CNM-Au8 in multiple sclerosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.